GB1600069A - Method for the measurement of antigens and antibodies - Google Patents
Method for the measurement of antigens and antibodies Download PDFInfo
- Publication number
- GB1600069A GB1600069A GB2395778A GB2395778A GB1600069A GB 1600069 A GB1600069 A GB 1600069A GB 2395778 A GB2395778 A GB 2395778A GB 2395778 A GB2395778 A GB 2395778A GB 1600069 A GB1600069 A GB 1600069A
- Authority
- GB
- United Kingdom
- Prior art keywords
- antibody
- antigen
- carrier particles
- reaction
- microns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 124
- 102000036639 antigens Human genes 0.000 title claims abstract description 124
- 108091007433 antigens Proteins 0.000 title claims abstract description 124
- 238000000034 method Methods 0.000 title claims abstract description 84
- 238000005259 measurement Methods 0.000 title abstract description 26
- 239000002245 particle Substances 0.000 claims abstract description 116
- 238000002835 absorbance Methods 0.000 claims abstract description 56
- 238000010521 absorption reaction Methods 0.000 claims abstract description 46
- 239000011541 reaction mixture Substances 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 229920000126 latex Polymers 0.000 claims description 56
- 239000000523 sample Substances 0.000 claims description 56
- 239000004816 latex Substances 0.000 claims description 53
- 238000006243 chemical reaction Methods 0.000 claims description 41
- 239000007788 liquid Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000004793 Polystyrene Substances 0.000 claims description 12
- 230000004520 agglutination Effects 0.000 claims description 12
- 229920002223 polystyrene Polymers 0.000 claims description 12
- 230000005540 biological transmission Effects 0.000 claims description 10
- 238000003127 radioimmunoassay Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 239000012429 reaction media Substances 0.000 claims description 6
- 239000012488 sample solution Substances 0.000 claims description 5
- 238000013019 agitation Methods 0.000 claims description 4
- 238000011088 calibration curve Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 210000000170 cell membrane Anatomy 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 229910052809 inorganic oxide Inorganic materials 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 229920003002 synthetic resin Polymers 0.000 claims description 3
- 239000000057 synthetic resin Substances 0.000 claims description 3
- 239000007822 coupling agent Substances 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 239000012470 diluted sample Substances 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 239000013026 undiluted sample Substances 0.000 claims 1
- 230000005855 radiation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 38
- 239000000243 solution Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 10
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 9
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 9
- 230000035484 reaction time Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- -1 e.g. Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000473945 Theria <moth genus> Species 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000282 fibrinogen degradation product Substances 0.000 description 2
- 229940106780 human fibrinogen Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 229920000620 organic polymer Polymers 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- UZKIAJMSMKLBQE-SUPAOECSSA-N (2s,3s,4s,5r)-6-[[(8r,9s,13s,14s,16r,17r)-16,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1C[C@@H](O)[C@@H]4O)C)CC2=CC=3OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O UZKIAJMSMKLBQE-SUPAOECSSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- KBLMVFQJBDDSPY-UHFFFAOYSA-N CCC(CCC1)CC1C1CCCC1 Chemical compound CCC(CCC1)CC1C1CCCC1 KBLMVFQJBDDSPY-UHFFFAOYSA-N 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical class OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000003023 adrenocorticotropic effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000431 corpus luteum hormone Substances 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000208 fibrin degradation product Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940056932 lead sulfide Drugs 0.000 description 1
- 229910052981 lead sulfide Inorganic materials 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 229920003217 poly(methylsilsesquioxane) Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000000411 transmission spectrum Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1532878A JPS54108695A (en) | 1978-02-15 | 1978-02-15 | Method and device for measuring antigennantibody reaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1600069A true GB1600069A (en) | 1981-10-14 |
Family
ID=11885701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2395778A Expired GB1600069A (en) | 1978-02-15 | 1978-05-30 | Method for the measurement of antigens and antibodies |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JPS54108695A (enExample) |
| BE (1) | BE874167R (enExample) |
| CH (1) | CH640640A5 (enExample) |
| DE (1) | DE2905434C2 (enExample) |
| FR (1) | FR2417771A2 (enExample) |
| GB (1) | GB1600069A (enExample) |
| NL (1) | NL188963C (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0028133A3 (en) * | 1979-10-26 | 1982-02-03 | Dynasciences Corporation | Method of detecting and quantitating haptens and antigens |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0737989B2 (ja) * | 1986-07-04 | 1995-04-26 | 東ソー株式会社 | 免疫反応の測定方法および装置 |
| US5198369A (en) * | 1990-04-25 | 1993-03-30 | Canon Kabushiki Kaisha | Sample measuring method using agglomeration reaction of microcarriers |
| DE4211351A1 (de) * | 1992-04-04 | 1993-10-07 | Behringwerke Ag | Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1384399A (en) * | 1971-02-01 | 1975-02-19 | Hoffmann La Roche | Automated method of obtaining serological data |
| JPS5811575B2 (ja) * | 1976-08-16 | 1983-03-03 | 帝国臓器製薬株式会社 | 抗原−抗体反応の測定法 |
| IT1087285B (it) * | 1976-11-10 | 1985-06-04 | Hoffmann La Roche | Procedimento di determinazione immunologico |
-
1978
- 1978-02-15 JP JP1532878A patent/JPS54108695A/ja active Pending
- 1978-05-30 GB GB2395778A patent/GB1600069A/en not_active Expired
- 1978-10-03 FR FR7828252A patent/FR2417771A2/fr active Granted
-
1979
- 1979-02-13 DE DE19792905434 patent/DE2905434C2/de not_active Expired
- 1979-02-14 BE BE0/193462A patent/BE874167R/xx not_active IP Right Cessation
- 1979-02-14 CH CH143379A patent/CH640640A5/de not_active IP Right Cessation
- 1979-02-15 NL NL7901205A patent/NL188963C/xx not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0028133A3 (en) * | 1979-10-26 | 1982-02-03 | Dynasciences Corporation | Method of detecting and quantitating haptens and antigens |
Also Published As
| Publication number | Publication date |
|---|---|
| NL188963C (nl) | 1992-11-16 |
| NL188963B (nl) | 1992-06-16 |
| DE2905434A1 (de) | 1979-08-16 |
| JPS54108695A (en) | 1979-08-25 |
| DE2905434C2 (de) | 1984-11-15 |
| BE874167R (fr) | 1979-08-14 |
| NL7901205A (nl) | 1979-08-17 |
| CH640640A5 (en) | 1984-01-13 |
| FR2417771B2 (enExample) | 1983-04-15 |
| FR2417771A2 (fr) | 1979-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4118192A (en) | Method and apparatus for the measurement of antigens and antibodies | |
| US4208185A (en) | Method and apparatus for the measurement of antigens and antibodies | |
| US4203724A (en) | Method and apparatus for the measurement of antigens and antibodies | |
| US4313929A (en) | Method of measurement of antigens and antibodies | |
| US4224304A (en) | Method and apparatus for the measurement of antigens and antibodies | |
| EP0298368B1 (en) | Non-metal colloidal particle immunoassay | |
| US4080264A (en) | Immunoassay by light scattering spectroscopy | |
| US4766083A (en) | Method for the photometric determination of biological agglutination | |
| US4521521A (en) | Particle reagent size distribution measurements for immunoassay | |
| US4174952A (en) | Immunoassay by light scattering intensity anisotropy measurements | |
| US4250394A (en) | Apparatus for determining immunochemical substances | |
| JPS5990053A (ja) | 抗原−抗体反応 | |
| US4213764A (en) | Method for determining immunochemical substances | |
| JPS6365369A (ja) | 抗原−抗体反応の測定法 | |
| JP4331073B2 (ja) | 抗原の測定方法及びそのための試薬 | |
| EP0269526B1 (en) | Method of quantitative determination of antigens and antibodies | |
| US4760030A (en) | Quantitative opaque particle agglutination assay | |
| GB1600139A (en) | Method and apparatus for the measurement of antigens and antibodies | |
| GB1600069A (en) | Method for the measurement of antigens and antibodies | |
| WO1998054578A1 (en) | Chemiluminescent hemoglobin assay | |
| EP0079962B1 (en) | Immunoprecipitation assay | |
| JPS6262291B2 (enExample) | ||
| CA1192490A (en) | Immunoprecipitation assay | |
| CA1112473A (en) | Method and combination for detecting specific binding substances | |
| JPH0421821B2 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed | ||
| PE20 | Patent expired after termination of 20 years |
Effective date: 19970815 |